HBRP PUBLICATION

Journal of Applied Nursing Research and Education
Volume 1 Issue 2

Symptoms, Treatment, Complications as well as Prognosis of Classic Maple Syrup Urine Disease (MSUD), Metabolic Instability, Neurological Complications and Treatment Of Intermediate MSUD, Case Studies as well as Success Stories of Thiamine Responsive MSUD

Vinayasree. C[1], Mohan Naidu. K[2], Muralinath. E*[3], Amrutham Sandeep[4], Venkat Naveen. A[5], Guruprasad. M[6], Sravani Pragna. K[7]

[1]Assistant Professor, College of Veterinary Science, Korutla, PVNRTVU, Telengana, Hyderabad, India

[2,5]Veterinay Doctor, College of veterinary science, Proddatur, Andhra Pradesh, India

[3]Associate Professor, College of veterinary science, Proddatur, Andhra Pradesh, India

[4]Staff, Indian Veterinary Research Institute (IVRI), Izathnagar 243122 Barielly district, Uttar Pradesh, India

[6]Assistant General Manager, Vaishnavi Bio pharma pvt. Ltd., Telanagana, India

[7]Assistant Professor, Contract Teaching Faculty, College of veterinary, science, Proddatur, Andhra Pradesh, India

***Corresponding Author**

E-Mail Id: muralinathennamuri@gmail.com

ABSTRACT

Maple Syrup Urine Disease (MSUD) is a rare inherited metabolic disorder manifested by the impaired catabolism of certain amino acids. This disorder results in the collection of toxic substances in the body, leading to a range of symptoms and complications. MSUD is categorized into different types dependent on the specific enzyme deficiencies involved in the disease. This review article aims to provide a comprehensive overview of the types of MSUD, along with their clinical features, genetic basis, diagnostic methods, and management strategies.

Keywords: *Genetic basis, diagnostic methods, management strategies, keto aciduria, Branched-chain alpha-ketoacid dehydrogenase (BCKD) complex, autosomal recessive disorders, neurological damage, poor feeding as well as growth, lethargy, irratability,seizures, muscle stiffness, leucine, isoleucine, valine, thiamine, lipoic acid, metabolic cries, vomiting, specific genetic mutation, catabolism of carbohydrates, proteins and fats, dietary management and early diagnosis*

INTRODUCTION

Maple Syrup Urine Disease (MSUD), also known as branched-chain ketoaciduria, is a rare but serious genetic metabolic disorder. It is named after the distinctive sweet smell of the urine especially in affected individuals, which resembles that of maple syrup. This article gives information about

understanding of MSUD from a medical standpoint, including its causes, types, clinical manifestations, diagnosis, treatment options, and ongoing research.[1-3]

Etiology and Genetic Basis

It primarily occurs by mutations in the genes that encode the enzymes participated in BCAA metabolism, particularly the branched-chain alpha-ketoacid dehydrogenase (BCKD) complex. The four subunits of this complex—E1α, E1β, E2, and E3—are affected in different types of MSUD. Mutations in these genes disturb the normal function of the BCKD complex, leading to the accumulation of BCAAs and their toxic metabolites.[4-6]

TYPES OF MSUD

- Classical MSUD
- Intermediate MSUD
- Intermittent MSUD
- Thiamine responsive MSUD

CLASSIC MSUD[11]

Classic MSUD is an autosomal recessive disorder manifested by mutations in the genes essential for producing enzymes that break down the amino acids leucine, isoleucine, and valine. The deficiency of functional enzymes results in the collection of these amino acids and their byproducts in the blood and tissues, causing neurological damage.

Symptoms

The name "maple syrup urine disease" stems from the characteristic sweet odor of the urine particularly in affected individuals. This distinct smell is a result of the collection of certain organic acids. Other common symptoms of classic MSUD are poor feeding and growth, lethargy, irritability, seizures, developmental delays, muscle stiffness, and eventually, severe neurological damage without treatment.

Diagnosis

Early diagnosis is critical for the management of classic MSUD. Newborn screening programs in many countries can detect enhanced levels of amino acids in the blood, permitting for early intervention. Confirmatory testing involves measuring the specific enzyme activities in the blood or identifying the genetic mutations responsible for the disorder.

Treatment

The primary goal of managing classic MSUD is to regulate normal levels of amino acids in the body. This is happened through a carefully controlled diet that restricts the intake of leucine, isoleucine, and valine. Specialized formulas and medical foods low in these amino acids are used to ensure proper nutrition while escaping excessive buildup. Regular monitoring of blood amino acid levels is responsible for making adjustments to the diet as needed.

In some cases, supplements containing thiamine (vitamin B1) are prescribed as it assists in improving the catabolism of amino acids and decrease their accumulation. Close medical supervision and ongoing support from a metabolic specialist are essential for optimizing treatment and minimize the risk of metabolic crises.

Complications and Prognosis

Without early diagnosis and proper management, classic MSUD can result in severe complications, along with intellectual disability, movement disorders, and life-threatening metabolic crises triggered by infections, fasting, or excessive protein intake. Long-term complications are chronic neurological impairment and enhanced vulnerability to neuro degenerative disorders.

However, with early detection through newborn screening and adherence to a strict dietary regimen, individuals with classic MSUD result in relatively normal lives. Advancements in medical knowledge and treatments showed more significance regarding the prognosis and quality of life for those with the condition.

Conclusion

Classic Maple Syrup Urine Disease (MSUD) is a rare genetic disorder manifested by by the body's inability to metabolize certain amino acids, leading to their toxic buildup and potential neurological damage. Early detection through newborn screening and adherence to a strict dietary regimen are very important for managing the condition and preventing severe complications. Ongoing medical supervision and support are critical to optimize treatment and provide the best possible outcomes for individuals with classic MSUD.

INTERMEDIATE MSUD[12,13]

Intermediate MSUD presents unique challenges compared to classic or intermittent MSUD. It is manifested by varying degrees of enzyme activity and metabolic instability. The enzyme responsible for catabolism of the amino acids leucine, isoleucine, and valine—known as the branched-chain alpha-keto acid dehydrogenase complex (BCKDC)—experiences decreased activity in intermediate MSUD. This results in a milder but still significant impairment in the body's ability to process these amino acids.

Challenges Faced by Individuals with Intermediate MSUD

Dietary Restrictions: Like other forms of MSUD, individuals with intermediate MSUD must bind with a strict low-protein diet. Controlling the intake of leucine, isoleucine, and valine is critical in obstructing metabolic crises and the collection of toxic byproducts. Dietary management often needs close supervision from doctors and careful monitoring of protein intake.

Metabolic Instability

Intermediate MSUD individuals experience metabolic instability, meaning their enzyme activity can fluctuate, leading to unpredictable responses to dietary modifications and other factors. This unpredictability can complicate treatment and require regular monitoring of blood amino acid levels to maintain metabolic stability.

Neurological Complications

While intermediate MSUD is generally less severe than the classic form, it still shows the risk of neurological complications. The collection of toxic substances can affect brain function, leading to developmental delays, intellectual disabilities, and behavioral problems. Early intervention and close

neurological monitoring are essential to mitigate these risks.

Treatment Options for Intermediate MSUD

Dietary management

A low-protein diet plays a major role in managing intermediate MSUD. Nutritional planning is related to careful calculation of protein intake, along with supplementation of essential amino acids and vitamins. Frequent monitoring of blood amino acid levels is critical in adjusting the diet as needed.

Medications

In some cases, medical interventions may be responsible for managing intermediate MSUD. Medications namely thiamine (vitamin B1) and lipoic acid can help optimize the function of the BCKDC enzyme, thereby supporting the breakdown of branched-chain amino acids. These medications should be used under the guidance of a doctor.

Genetic counseling

Genetic counseling is beneficial for individuals with intermediate MSUD and their families. Understanding the inheritance patterns and the risk of passing on the condition to future generations can assist in family planning decisions. Genetic counseling also gives an information regarding potential treatment advances and ongoing research.

Psycho social support

Coping with a chronic condition like intermediate MSUD can be emotionally challenging. Psychosocial support, along with counseling and support groups, can help individuals and their families manage the psychological and social aspects of living with this rare disorder.

Conclusion

Intermediate MSUD poses unique challenges compared to other forms of the condition, requiring diligent dietary management, regular monitoring, and possible medical interventions. Individuals with intermediate MSUD and their families must work in close association with doctor to optimize treatment and decrease the risk of metabolic crises and neurological complications. Advances in genetic research and ongoing studies result in further understanding and enhanced management strategies for this complex disorder in the future.

INTERMITTENT MSUD[14,15]

Intermittent MSUD is a milder variant of the classic form of MSUD. Unlike the classic form, where individuals exhibit a constant inability to metabolize the amino acids leucine, isoleucine, and valine, intermittent MSUD permits for periods of normal metabolism and periods of impaired metabolism. This intermittent nature gives an information to individuals with more flexibility in managing their condition while still requiring careful attention to diet and regular monitoring.

Symptoms and Diagnosis

The symptoms of intermittent MSUD can vary from person to person and can manifest during episodes of impaired metabolism. These symptoms are poor feeding, vomiting, lethargy, developmental delays, and a distinct odor resembling maple syrup in the urine or sweat.

Diagnosing intermittent MSUD often involves a combination of clinical evaluation, biochemical testing, and genetic analysis. Blood tests can measure the levels of amino acids and their byproducts, while genetic testing can identify the specific genetic mutations linked to the condition.

Managing Intermittent MSUD

Dietary management is a critical aspect of managing intermittent MSUD. Individuals with intermittent MSUD must carefully control their intake of protein-rich foods, especially those containing the amino acids leucine, isoleucine, and valine. This typically involves working closely with a registered dietitian to develop a customized meal plan that ensures adequate nutrition while reducing the risk of metabolic crises.

Medical supervision and regular monitoring play a role in managing intermittent MSUD. Regular blood tests are conducted to monitor the levels of amino acids and their metabolites, allowing doctors to adjust the dietary plan as needed. In some cases, individuals may need medical formula supplements or special formulas that provide the necessary amino acids without the ones that cannot be metabolized.

Support and Education

Living with intermittent MSUD can present unique challenges, but with the right support and education, individuals and their families can effectively manage the condition. Connecting with support groups and organizations specializing in MSUD give valuable resources, information, and a network of individuals who understand the daily challenges of living with this condition.

It is critical for individuals with intermittent MSUD to develop a comprehensive support system that includes doctors, family members, and close friends. Open communication, adherence to the prescribed treatment plan, and a proactive approach to monitoring symptoms and dietary intake are responsible for managing intermittent MSUD successfully.

Conclusion

Intermittent MSUD is a rare genetic disorder that permits individuals to experience periods of normal metabolism, arranging them with more flexibility in managing their condition. While it still requires careful dietary management and regular monitoring, individuals with intermittent MSUD result in fulfilling lives with proper support, education, and adherence to a personalized treatment plan. By working closely with doctors, following a specialized diet, and staying informed about the latest research and advancements, individuals with intermittent MSUD can effectively navigate the challenges closely linked with with this condition.

THIAMINE RESPONSIVE MSUD[16,17]

Thiamine Responsive MSUD is a sub type of MSUD that responds favorably to more doses of thiamine, also termed as vitamin B1. This condition occurs due to a specific genetic mutation that influences the transport of thiamine into the cells, resulting in reduced levels of thiamine particularly within the cells. Without

sufficient thiamine, the enzymes responsible for breaking down the toxic amino acids become inactive, leading to the collection of these amino acids in the body.

Thiamine's Role in Treatment

Thiamine is an essential vitamin that plays a vital role in energy metabolism. It behaves as a coenzyme for several enzymes participated in the catabolism of carbohydrates, proteins, and fats, ensuring that the body can efficiently change food into energy. In the case of Thiamine Responsive MSUD, more doses of thiamine can bypass the faulty transport mechanism, permitting thiamine to enter the cells and activate the enzymes responsible for breaking down the toxic amino acids.

The effectiveness of thiamine in treating Thiamine Responsive MSUD is remarkable. When individuals with this condition receive high-dose thiamine therapy, the levels of toxic amino acids in their blood and tissues decrease in a significant manner. This reduction helps prevent the onset of symptoms and can even reverse living neurological complications.

Thiamine Responsive MSUD: Case Studies and Success Stories

Numerous case studies and success stories have identified the positive impact of thiamine therapy in individuals with Thiamine Responsive MSUD. These stories reveal the life-changing effects of early diagnosis and treatment.

In one notable case, a child diagnosed with Thiamine Responsive MSUD experienced rapid improvement after starting thiamine treatment. The child's seizures ceased, and their developmental milestones enhanced in a significant manner. This case, along with others, identifies the importance of early intervention and the crucial role of thiamine in managing the condition.

Ongoing Research and Future Directions

While thiamine therapy has proven to be effective in managing Thiamine Responsive MSUD, ongoing research continues to explore new treatment modalities and advancements in the field. Gene therapy, for example, confirms promise as a potential long-term solution for individuals with MSUD by addressing the underlying genetic mutation responsible for the condition.

Furthermore, genetic counseling and prenatal testing play critical roles in identifying carriers and providing families with valuable information regarding their risk of having a child with Thiamine Responsive MSUD. Early detection permits for prompt treatment initiation, leading to improved outcomes for affected individuals.

Conclusion

Thiamine Responsive MSUD offers hope for individuals affected by this rare metabolic disorder. With high-dose thiamine therapy, individuals can expertise a significant reduction in toxic amino acid levels, obstructing the onset of symptoms and improving overall quality of life. Ongoing research and advancements in genetic therapies further hold promise for the future management of Thiamine Responsive MSUD.

ONGOING RESEARCH AND EMERGING THERAPIES

Scientific advancements have paved the way for ongoing research in MSUD. Gene therapy, which aims to rectify the genetic defect causing the disease, holds promise as a potential treatment option. In addition to this, novel therapeutic approaches, such as pharmacological modulation of the BCKD complex and liver transplantation, are being explored to improve outcomes for individuals with MSUD.[18,19]

PSYCHO SOCIAL IMPLICATIONS AND SUPPORT

Living with MSUD can have a profound impact on affected individuals and their families. Coping with the demands of dietary management, regular monitoring, and potential complications can be challenging. Support from doctors, genetic counselors, and patient support groups is vital in addressing psycho social needs, providing education, and fostering a sense of community.

CONCLUSION

Maple Syrup Urine Disease is a rare genetic metabolic disorder manifested by by the impaired catabolism of branched-chain amino acids. Early diagnosis, dietary management, and ongoing monitoring are critical for obstructing neurological complications and optimizing outcomes. While significant progress has been made in understanding and managing MSUD, ongoing research and emerging therapies offer hope for improved treatment options in the future.

REFERENCES

1. Edelmann, L., Wasserstein, M. P., Kornreich, R., Sansaricq, C., Snyderman, S. E., & Diaz, G. A. (2001). Maple syrup urine disease: identification and carrier-frequency determination of a novel founder mutation in the Ashkenazi Jewish population. *The American Journal of Human Genetics*, *69*(4), 863-868.
2. Blackburn, P. R., & Gass, J. M. (2017). e Vairo FP, Farnham KM, Atwal HK, Macklin S, Klee EW, et al. Maple syrup urine disease: mechanisms and management. Appl. *Clin. Genet*, *10*, 57.
3. Strauss, K. A., Puffenberger, E. G., & Carson, V. J. (2020). Maple syrup urine disease.
4. Quental, S., Macedo-Ribeiro, S., Matos, R., Vilarinho, L., Martins, E., Teles, E. L., ... & Prata, M. J. (2008). Molecular and structural analyses of maple syrup urine disease and identification of a founder mutation in a Portuguese Gypsy community. *Molecular genetics and metabolism*, *94*(2), 148-156.
5. Suryawan, A., Hawes, J. W., Harris, R. A., Shimomura, Y., Jenkins, A. E., & Hutson, S. M. (1998). A molecular model of human branched-chain amino acid metabolism. *The American journal of clinical nutrition*, *68*(1), 72-81.
6. Lynch, C. J., & Adams, S. H. (2014). Branched-chain amino acids in metabolic signalling and insulin resistance. *Nature Reviews Endocrinology*, *10*(12), 723-736.
7. Morton, D. H., Strauss, K. A., Robinson, D. L., Puffenberger, E. G., & Kelley, R. I
8. Scaini, G., Morais, M. O., Galant, L. S., Vuolo, F., Dall'Igna, D. M., Pasquali, M. A., ... & Streck, E. L.

(2014). Coadministration of branched-chain amino acids and lipopolysaccharide causes matrix metalloproteinase activation and blood–brain barrier breakdown. *Molecular neurobiology*, *50*, 358-367.

9. Hallam, P., Lilburn, M., & Lee, P. J. (2005). A new protein substitute for adolescents and adults with maple syrup urine disease (MSUD). *Journal of inherited metabolic disease*, *28*(5), 665-672.
10. Frazier, D. M., Allgeier, C., Homer, C., Marriage, B. J., Ogata, B., Rohr, F., ... & Singh, R. H. (2014). Nutrition management guideline for maple syrup urine disease: an evidence-and consensus-based approach. *Molecular genetics and metabolism*, *112*(3), 210-217.
11. Hoffmann, B., Helbling, C., Schadewaldt, P., & Wendel, U. (2006). Impact of longitudinal plasma leucine levels on the intellectual outcome in patients with classic MSUD. *Pediatric research*, *59*(1), 17-20.
12. Abi- Wardé, M. T., Roda, C., Arnoux, J. B., Servais, A., Habarou, F., Brassier, A., ... & de Lonlay, P. (2017). Long- term metabolic follow- up and clinical outcome of 35 patients with maple syrup urine disease. *Journal of Inherited Metabolic Disease: Official Journal of the Society for the Study of Inborn Errors of Metabolism*, *40*(6), 783-792.
13. Strauss, K. A., Wardley, B., Robinson, D., Hendrickson, C., Rider, N. L., Puffenberger, E. G., ... & Morton, D. H. (2010). Classical maple syrup urine disease and brain development: principles of management and formula design. *Molecular genetics and metabolism*, *99*(4), 333-345.
14. Brunetti-Pierri, N., Lanpher, B., Erez, A., Ananieva, E. A., Islam, M., Marini, J. C., ... & Lee, B. (2011). Phenylbutyrate therapy for maple syrup urine disease. *Human molecular genetics*, *20*(4), 631-640.
15. Muelly, E. R., Moore, G. J., Bunce, S. C., Mack, J., Bigler, D. C., Morton, D. H., & Strauss, K. A. (2013). Biochemical correlates of neuropsychiatric illness in maple syrup urine disease. *The Journal of clinical investigation*, *123*(4), 1809-1820.
16. Shellmer, D. A., DeVito Dabbs, A., Dew, M. A., Noll, R. B., Feldman, H., Strauss, K. A., ... & Mazariegos, G. V. (2011). Cognitive and adaptive functioning after liver transplantation for maple syrup urine disease: a case series. *Pediatric transplantation*, *15*(1), 58-64.
17. Shellmer, D. A., DeVito Dabbs, A., Dew, M. A., Noll, R. B., Feldman, H., Strauss, K. A., ... & Mazariegos, G. V. (2011). Cognitive and adaptive functioning after liver transplantation for maple syrup urine disease: a case series. *Pediatric transplantation*, *15*(1), 58-64.
18. Bouchereau, J., Leduc-Leballeur, J., Pichard, S., Imbard, A., Benoist, J. F., Abi Warde, M. T., ... & Schiff, M. (2017). Neurocognitive profiles in MSUD school-age patients. *Journal of inherited metabolic disease*, *40*, 377-383.

19. Couce, M. L., Ramos, F., Bueno, M. A., Díaz, J., Meavilla, S., Bóveda, M. D., ... & García-Cazorla, A. (2015). Evolution of maple syrup urine disease in patients diagnosed by newborn screening versus late diagnosis. *European Journal of Paediatric Neurology*, *19*(6), 652-659.